Stronger Starts
Maximize patient access and therapy starts.
Achieve an industry-leading 2x+ first fill rate vs. traditional channels, ensuring your therapy reaches as many patients as possible.
GTN Performance Calculator
Your brand team is focused on improving starts, coverage, and adherence. See what’s possible when all three components kick into hyperdrive to multiply gross‑to‑net impact, with an alternative channel built to maximize commercial control and patient outcomes. Uncover your brand’s untapped potential.
Uncover Your Commercial Potential
The outputs from this calculator aren’t generic industry averages. They are based on real program data from pharma brands working with PHIL.
Every calculation is based on real performance data from brands, giving you a realistic estimate of what's achievable for your portfolio.
The calculator is built to deliver a strong GTN estimate based on your brand's actual channel strategy inputs, layered on top of PHIL program data, not a generic industry average.
The model behind this calculator was built by PHIL's Commercial Insights team, translating the framework we use with our pharma clients into a self‑serve tool that commercial leaders can leverage.
The Opportunity
PHIL has 10+ years experience helping pharma teams improve their commercial performance through technology. Our all‑in‑one solution is built to optimize starts, coverage, and adherence to maximize gross‑to‑net impact.
Stronger Starts
Achieve an industry-leading 2x+ first fill rate vs. traditional channels, ensuring your therapy reaches as many patients as possible.
Higher Coverage
Drive 85%+ PA submission rates and 2x+ covered dispenses vs. traditional channels.
Better Adherence
Build a sustainable refill process that ensures patients can easily stay on therapy, with 3x+ refill adherence rates vs. traditional channels.
Multiplied Impact
Experience the compounding effect on commercial performance with PHIL.
We've seen outstanding commercial results with PHIL, stronger than any of our best case scenario forecasts.